Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2003 9
2004 10
2005 12
2006 17
2007 4
2008 3
2009 22
2010 32
2011 23
2012 10
2013 18
2014 21
2015 46
2016 58
2017 56
2018 69
2019 49
2020 44
2021 47
2022 60
2023 50
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Results by year

Filters applied: . Clear all
Page 1
Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.
Thomson A, Castillo C, Graefen H, Perera S, Lawrentschuk N, Perera M, Eapen R, Murphy DG. Thomson A, et al. Among authors: lawrentschuk n. Eur Urol. 2024 Apr 16:S0302-2838(24)02256-5. doi: 10.1016/j.eururo.2024.03.028. Online ahead of print. Eur Urol. 2024. PMID: 38631995 No abstract available.
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Chen DC, AlSaffar H, Graefen H, Perera S, Mazzone E, Perera ML, Lawrentschuk N, Murphy DG. Chen DC, et al. Among authors: lawrentschuk n. Eur Urol. 2024 Apr 16:S0302-2838(24)02260-7. doi: 10.1016/j.eururo.2024.03.032. Online ahead of print. Eur Urol. 2024. PMID: 38631993 No abstract available.
Corrigendum to "RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned" [Eur. Urol. Open Sci. 54 (2023) 33-42].
Agarwal DK, Mulholland C, Koye DN, Sathianathen N, Yao H, Dundee P, Moon D, Furrer M, Giudice C, Wang W, Simpson JA, Kearsley J, Norris B, Zargar H, Pan HYC, Mottrie A, Fuller A, Mottaran A, Challacombe B, Kua B, Metcalfe C, Wagner C, Dubey D, Gomez Sancha F, Bruyère F, Gautam G, Pooleri GK, Bozzini G, Lau H, Thyer I, Teoh J, Vass J, Vivian J, McDermott K, Winter M, Ragavan N, Campbell N, Harke NN, Richard PO, Teloken P, Dekuyper P, Sutherland P, Ahlawat R, Nair R, Pemberton R, Catterwell R, Oomen RJA, Weston R, Moritz R, Krishnappa RS, Leslie S, Van Appledorn S, Yuvaraja TB, Meert T, Dujardin T, Gross T, Walton T, Huang WC, Caumartin Y, Agarwal A, Lawrentschuk N, Corcoran NM. Agarwal DK, et al. Among authors: lawrentschuk n. Eur Urol Open Sci. 2024 Mar 16;63:2-3. doi: 10.1016/j.euros.2024.03.001. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38523653 Free PMC article.
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
Merseburger AS, Bakshi G, Chen DY, Chiong E, Jabbour M, Joung JY, Lai AY, Lawrentschuk N, Le TA, Ng CF, Ng CT, Ong TA, Pang JS, Rabah DM, Ragavan N, Sase K, Suzuki H, Teo MMH, Uemura H, Woo HH. Merseburger AS, et al. Among authors: lawrentschuk n. World J Urol. 2024 Mar 14;42(1):156. doi: 10.1007/s00345-024-04852-2. World J Urol. 2024. PMID: 38483562 Free PMC article. Review.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Siva S, et al. Among authors: lawrentschuk n. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. Lancet Oncol. 2024. PMID: 38423047 Clinical Trial.
The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis.
Lindsay D, Schofield P, Nabukalu D, Roberts MJ, Yaxley J, Quinn S, Richards N, Frydenberg M, Gardiner R, Lawrentschuk N, Juraskova I, Murphy DG, Gordon LG. Lindsay D, et al. Among authors: lawrentschuk n. Aust Health Rev. 2024 Feb;48:AH23231. doi: 10.1071/AH23231. Aust Health Rev. 2024. PMID: 38342484 Clinical Trial.
566 results